(DNTH)

Reporting relationship: Director
Issuer ticker: DNTH
Reported as of: 23 May 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 May 2024, 19:57:52 UTC
Prior SEC filing: 16 May 2024
Next SEC filing: 07 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC

Key filing fact

Fairmount Funds Management LLC filed Form 4 for Dianthus Therapeutics, Inc. /DE/ (DNTH) on 28 May 2024.

Key facts

This page summarizes Fairmount Funds Management LLC's Form 4 filing for Dianthus Therapeutics, Inc. /DE/ (DNTH).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 May 2024, 19:57.

Change

Previous filing in this sequence was filed on 16 May 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DNTH transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +11,000
Change %
Price: $0.000000
Shares after: 11,000
Date: 23 May 2024
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 11,000
Exercise price: $21.77
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to Tomas Kiselak's continued service to the Issuer through the vesting date.

Footnote F2

Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC ("Fairmount"), Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therin.

SEC remarks

Fairmount may be deemed a director by deputization of the Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of the Issuer and is a Managing Member of Fairmount.